New York, New York 10028

  • Atrophic Acne Scar

Purpose:

This pilot study will expand knowledge and application needling using the Epistamp device for the improvement of Atrophic Acne Scarring


Study summary:

This pilot study will expand the knowledge and application of needling using the Epistamp device and its safety and benefits for improving the appearance of atrophic acne scarring. The pilot aims to objectively measure skin quality using the Derma Scan, photographs and provide objective data showing improvement by way of the Goodman and Barons quantitative scar scale.


Criteria:

Inclusion Criteria: - Derma Scan showing aging including skin texture, wrinkles, brown spots, and pores. - Patients willing to sign informed consent. - Patients willing to be photographed and video documented - Patients willing to consent to 3 months of treatment Exclusion Criteria: - History of eczema in the treatment area; psoriasis and any other chronic skin conditions - History of actinic (solar) keratosis in the treatment area; - History of hemophilia - History of diabetes - The presence of raised moles, warts on the targeted area. - Collagen vascular diseases or cardiac abnormalities - Blood clotting problems - Active bacterial or fungal infection - Facial melanosis - Malignant tumors - Immunosuppression - Use of blood thinners or prednisone - Corticosteroids within two weeks of the procedure - Chronic liver disease - Porphyria or other skin diseases. - Patient not willing to sign informed consent. - TCA peels in the last 5 weeks - Subject currently has moderate to severe acne on the face. - Microneedling within the last 6 months - Subject has an active infection. - Subject has a history of a bleeding disorder - Subject has a history of keloidal tendency - Subject has received ablative or non-ablative laser treatments in the previous 6 months. - Subject has taken Accutane within the previous 3 months.


NCT ID:

NCT04740268


Primary Contact:

Principal Investigator
Maurice E Wright, DR
Columbia University

Leslie Nesbitt, Tech
Phone: 6468384154
Email: trials@universalskincareinstitute.com


Backup Contact:

Michelle Jenkins, Tech
Phone: 6468384154


Location Contact:

New York, New York 10028
United States

Leslie Nesbitt, Tech
Phone: 646-838-4154
Email: trials@universalskincareinstitute.com

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 21, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.